TLR2 and Alzheimer disease: In sensory neurons (mDRGs), pre-treatment with Pam3CSK4 significantly increased the release of cytokines like chemerin in response to IL-13. It suggests that the interplay between IL-13 and TLR2 signaling pathways is crucial in driving neurogenic inflammation in AD.